SCHEMBL22493400

SCHEMBL22493400

CC(C)(C)NCC(O)c1cccc(C(F)(F)F)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 3/20 1.00
ADRB2 P07550 5/20 0.53
HIF1A Q16665 4/20 0.51
LMNA P02545 2/20 0.51
CYP2D6 P10635 3/20 0.43
NFKB1 P19838 2/20 0.43
BLM P54132 1/20 0.42
IDH1 O75874 1/20 0.41
IDH2 P48735 1/20 0.41
P2RX7 Q99572 1/20 0.40
TSHR P16473 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CASP7 P55210 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22481182 1.00 ADRB1 (1.00) ADRB1ADRB2HIF1ALMNACYP2D6
SCHEMBL22481240 1.00 ADRB1 (1.00) ADRB1ADRB2HIF1ALMNACYP2D6
SCHEMBL22481253 0.91 ADRB1 (0.84) ADRB1ADRB2HIF1ALMNACYP2D6
SCHEMBL22481281 0.91 ADRB1 (0.84) ADRB1ADRB2HIF1ALMNACYP2D6
SCHEMBL22490270 0.88 ADRB1 (0.78) ADRB1ADRB2HIF1ALMNACYP2D6
SCHEMBL22481139 0.88 ADRB1 (0.78) ADRB1ADRB2HIF1ALMNACYP2D6
SCHEMBL22481243 0.84 ADRB1 (0.72) ADRB1ADRB2IDH1IDH2P2RX7
SCHEMBL22481236 0.82 ADRB1 (0.70) ADRB1ADRB2HIF1ALMNACYP2D6
SCHEMBL22481160 0.82 ADRB1 (0.70) ADRB1ADRB2HIF1ALMNACYP2D6
SCHEMBL22481290 0.82 ADRB1 (0.69) ADRB1ADRB2HIF1ALMNACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137506-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
WO-2023225021-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) CURASEN THERAPEUTICS, INC. (US) 2023-11-23 WO disclosed
US-20230263749-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. 2023-08-24 US disclosed
WO-2020198466-A9 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
WO-2020198466-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263749-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS ADRA2A, SNCA, ADRA1A ADRB1 5/4885ADRB2 4/4885HIF1A 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.